Randomized Controlled Trial Evaluating the Use of Zoledronic Acid in Duchenne Muscular Dystrophy

Abstract Context Patients with glucocorticoid-dependent Duchenne muscular dystrophy (DMD) have increased fracture risk and reduced bone mineral density (BMD), often precipitating mobility loss. Objective To investigate use of zoledronic acid (ZA) in DMD in improving BMD. Methods Two arm, parallel, r...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The journal of clinical endocrinology and metabolism 2021-08, Vol.106 (8), p.2328-2342
Hauptverfasser:	Zacharin, Margaret, Lim, Angelina, Gryllakis, James, Siafarikas, Aris, Jefferies, Craig, Briody, Julie, Heather, Natasha, Pitkin, Janne, Emmanuel, Jaiman, Lee, Katherine J, Wang, Xiaofang, Simm, Peter J, Munns, Craig F
Format:	Artikel
Sprache:	eng
Schlagworte:	Alfacalcidol Bone mineral density Bone turnover Bones Calcifediol Children's hospitals Clinical trials Computed tomography Density Dual energy X-ray absorptiometry Duchenne muscular dystrophy Duchenne's muscular dystrophy Evaluation Fractures Glucocorticoids Mobility Muscular dystrophy Pain Pediatrics Physically disabled persons Radius Spine (lumbar) Standard scores Tibia Vertebrae Vitamin D Zoledronic acid
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!